It was our hypothesis that a local release of TGF‐β inhibitor within the tumor microenvironment could promote neutrophil polarization into the antitumor N1 phenotype, and enhance pancreatic cancer response to combined IRE and αPD1 treatment. This evidence concerns the gene TGFB1 and pancreatic neoplasm.